1 |
Sim FH, Unni KK, Beabout JW, et al.Osteosarcoma with small cells simulating Ewing's tumor [J].J Bone Joint Surg Am, 1979, 61(2):207-215.
|
2 |
Nakajima H, Sim FH, Bond JR, et al.Small cell osteosarcoma of bone:Review of 72 cases[J].Cancer, 1997, 79(11): 2095-2106.
|
3 |
蒋智铭, 黄文涛, 张惠箴.小细胞性骨肉瘤14 例临床病理分析 [J].临床与实验病理学杂志, 2012, 28(6): 643-646.
|
4 |
Hiemcke-Jiwa LS, Sumathi VP, Baumhoer D, et al.Small cell osteosarcoma versus fusion-driven round cell sarcomas of bone:retrospective clinical, radiological, pathological, and (epi)genetic comparison with clinical implications [J].Virchows Arch, 2024,484(3): 451-463.
|
5 |
Righi A, Gambarotti M, Longo S, et al.Small cell osteosarcoma:clinicopathologic, immunohistochemical, and molecular analysis of 36 cases [J].Am J Surg Pathol, 2015, 39(5): 691-699.
|
6 |
Bishop JA, Shum CH, Sheth S, et al.Small cell osteosarcoma:cytopathologic characteristics and differential diagnosis [J].Am J Clin Pathol, 2010, 133(5): 756-761.
|
7 |
刘丽丽, 沈丹华.小细胞骨肉瘤16 例临床病理特征 [J].临床与实验病理学杂志, 2021, 37(7): 830-832.
|
8 |
Kilpatrick SE, Reith JD, Rubin B.Ewing sarcoma and the history of similar and possibly related small round cell tumors: From whence have we come and where are we going? [J].Adv Anat Pathol, 2018,25(5): 314-326.
|
9 |
Balamuth NJ, Womer RB.Ewing’s sarcoma [J].Lancet Oncol, 2010,11(2): 184-192.
|
10 |
Zhong J, Hu Y, Si L, et al.Clarifying prognostic factors of small cell osteosarcoma: A pooled analysis of 20 cases and the literature [J].J Bone Oncol, 2020, 24: 100305.
|
11 |
Klein MJ, Siegal GP.Osteosarcoma: anatomic and histologic variants[J].Am J Clin Pathol, 2006, 125(4): 555-581.
|
12 |
Yarmish G, Klein MJ, Landa J, et al.Imaging characteristics of primary osteosarcoma: nonconventional subtypes [J].Radiographics,2010, 30(6): 1653-1672.
|
13 |
Nair N.Bone scanning in Ewing's sarcoma [J].J Nucl Med, 1985,26(4): 349-352.
|
14 |
Rossleigh MA, Smith J, Yeh SD.Scintigraphic features of primary sacral tumors [J].J Nucl Med, 1986, 27(5): 627-630.
|
15 |
Muckle M, Habibi E, Simon B, et al.Appearance of extraosseous pelvic Ewing sarcoma on triphasic bone scan [J].Clin Nucl Med,2014, 39(4): 406-408.
|
16 |
Newman EN, Jones RL, Hawkins DS.An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan,and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma [J].Pediatr Blood Cancer, 2013, 60(7): 1113-1117.
|
17 |
Byun BH, Kong CB, Lim I, et al.Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma [J].Skeletal Radiol, 2013, 42(12): 1673-1681.
|
18 |
Vriens D, Arens AI, de Rooy JW, et al.Hardware failure: a potential pitfall in assessing recurrent Ewing's sarcoma on bone scintigraphy [J].Clin Nucl Med, 2010, 35(6): 430-433.
|
19 |
Ulaner GA, Magnan H, Healey JH, et al.Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?[J].AJR Am J Roentgenol, 2014, 202(4): 859-867.
|
20 |
Alves CRR, Faria DP, Carneiro CG, et al.18F-Fluoride PET/CT and 99mTc-MDP SPECT/CT can detect bone cancer at early stage in rodents [J].Life Sci, 2018, 206: 29-34.
|
21 |
Iarŭmov N, Vasilev N, Petkov K.Osteosarkoma na opashnata kost[Osteosarcoma of the coccyx] [J].Khirurgiia (Sofiia), 1997, 50(4): 55-56.
|
22 |
Padwal J, Baratto L, Chakraborty A, et al.PET/MR of pediatric bone tumors: what the radiologist needs to know [J].Skeletal Radiol, 2023,52(3): 315-328.
|
23 |
Schäfer JF, Gatidis S, Schmidt H, et al.Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology:initial results [J].Radiology, 2014, 273(1): 220-231.
|
24 |
丁宜, 席越, 孙晓琪, 等.骨小细胞恶性肿瘤套针穿刺活检与术后病理诊断比较 [J].中华病理学杂志, 2013, 42(3): 163-167.
|
25 |
Ayala AG, Ro JY, Raymond AK, et al.Small cell osteosarcoma.A clinicopathologic study of 27 cases [J].Cancer, 1989, 64(10): 2162-2173.
|
26 |
Machado I, Alberghini M, Giner F, et al.Histopathological characterization of small cell osteosarcoma with immunohistochemistry and molecular genetic support.A study of 10 cases [J].Histopathology, 2010, 57(1):162-167.
|
27 |
Dragoescu E, Jackson-Cook C, Domson G, et al.Small cell osteosarcoma with Ewing sarcoma breakpoint region 1 gene rearrangement detected by interphase fluorescence in situ hybridization [J].Ann Diagn Pathol, 2013,17(4): 377-382.
|
28 |
Grier HE, Krailo MD, Tarbell NJ, et al.Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone [J].N Engl J Med, 2003,348(8): 694-701.
|
29 |
Cidre-Aranaz F, Watson S, Amatruda JF, et al.Small round cell sarcomas [J].Nat Rev Dis Primers, 2022, 8(1): 66.
|
30 |
Amer HW, Algadi HH, Hamza SA.Mandibular small cell osteosarcoma: a case report and review of literature [J].J Egypt Natl Canc Inst, 2023, 35(1): 30.
|
31 |
Hingorani P, Zhang W, Zhang Z, et al.Trastuzumab deruxtecan,antibody-drug conjugate targeting HER2, Is effective in pediatric malignancies: A report by the pediatric preclinical testing consortium[J].Mol Cancer Ther, 2022, 21(8): 1318-1325.
|
32 |
Shen J, Guo W, Wang J, et al.ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, openlabel, single-arm, phase 1 study [J].J Clin Oncol, 2023, 41(16_suppl):11530-11530.
|
33 |
Tang Q, Zhu X, Song G, et al.Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate as neoadjuvant therapy for osteosarcoma: A single-arm, exploratory phase II trial [J].J Clin Oncol, 2023, 41(16_suppl): 11526-11526.
|
34 |
Attia S, Bolejack V, Ganjoo KN, et al.A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results [J].Cancer Med, 2023, 12(2):1532-1539.
|
35 |
Mirabello L, Troisi RJ, Savage SA.Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance,Epidemiology, and End Results Program [J].Cancer, 2009, 115(7):1531-1543.
|
36 |
Duchman KR, Gao Y, Miller BJ.Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology,and end results (SEER) program database [J].Cancer Epidemiol, 2015,39(2): 189-195.
|
37 |
Bielack SS, Kempf-Bielack B, Delling G, et al.Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols [J].J Clin Oncol, 2002, 20(3): 776-790.
|
38 |
Bacci G, Longhi A, Ferrari S, et al.Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years [J].Tumori,2004, 90(5): 478-484.
|
39 |
Bacci G, Longhi A, Versari M, et al.Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy:15-year experience in 789 patients treated at a single institution [J].Cancer, 2006, 106(5): 1154-1161.
|
40 |
Fu Y, Lan T, Cai H, et al.Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma [J].Medicine (Baltimore), 2018, 97(19):e0741.
|
41 |
Kelley LM, Schlegel M, Hecker-Nolting S, et al.Pathological fracture and prognosis of high-grade osteosarcoma of the extremities: An analysis of 2,847 consecutive cooperative osteosarcoma study group(COSS) patients [J].J Clin Oncol, 2020, 38(8): 823-833.
|